Clinical Trial Update: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating 9MW2821 in combination with toripalimab versus standard chemotherapy for locally advanced or metastatic urothelial carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• 9MW2821
• Toripalimab (Toripalimab)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Urothelial Carcinoma | Phase 3 | Status: RECRUITING